A recent study reveals that people who come off popular GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who end traditional lifestyle regimens.
Research printed in a major health publication shows that while overweight individuals often shed about a fifth of their total mass while on the medication, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users using these treatments should be aware of the potential of rapid weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a return to starting weight in about one and a half years.
Comparing Approaches
The research, which looked at dozens of trials involving thousands of participants, contrasted the outcomes of these new drugs with other pills.
The team note that people who lose weight through diet and exercise typically have a less rapid weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Nutrition scientists suggest the mode of action of the jabs is key to understanding the heightened rebound.
The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of GLP-1 levels several times higher than the body's typical production could lead to the body to produce less of its own natural GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making overeating far more likely."
A Chronic Condition?
The NHS suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts argue that, given the likelihood of relapse, the treatment is often ongoing.
This perspective is supported by pharmaceutical companies, who say that the results "highlight the persistent nature of obesity," akin to managing diseases like high blood pressure.
User Testimonies
Users who have come off the medication describe a sudden resurgence of appetite.
"It was like something activating and you become starving," recalled one woman.
This challenge is compounded if patients have not developed permanent lifestyle or habit changes during therapy.
Widespread Adoption
Figures indicate that millions of adults in the UK have tried these injections in the past year, with demand being substantial.
- Use is higher among females compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone solution and lasting health benefits likely depends on integrated behavioural management.
